Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane …
…, T Dawson, A Holland, TM John… - Clinical infectious …, 2010 - academic.oup.com
Background. In the absence of an efficacious broadly protective vaccine, serogroup B Neisseria
meningitidis (MenB) is the leading cause of bacterial meningitis and septicemia in many …
meningitidis (MenB) is the leading cause of bacterial meningitis and septicemia in many …
Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial
MD Snape, KP Perrett, KJ Ford, TM John, D Pace… - Jama, 2008 - jamanetwork.com
Context Immunization with a meningococcal tetravalent (serogroup ACWY) glycoconjugate
vaccine is recommended for all US adolescents. However, the currently licensed vaccine is …
vaccine is recommended for all US adolescents. However, the currently licensed vaccine is …
Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial
…, T Dawson, P Oster, A Evans, TM John… - The Pediatric …, 2010 - journals.lww.com
Background: An investigational vaccine against serogroup B meningococcal (MenB) disease
containing 3 main recombinant proteins (factor H-binding protein, Neisserial adhesion A, …
containing 3 main recombinant proteins (factor H-binding protein, Neisserial adhesion A, …
Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active …
…, CL Klinger, ED Daniels, TM John… - The Pediatric …, 2010 - journals.lww.com
Background: A 2-, 4-, and 12-month schedule of a novel 13-valent-pneumococcal conjugate
vaccine (PCV13), containing serotype 1, 3, 4, 5, 6A, 6B 7F, 9V, 14, 18C, 19A, 19F, and 23F …
vaccine (PCV13), containing serotype 1, 3, 4, 5, 6A, 6B 7F, 9V, 14, 18C, 19A, 19F, and 23F …
[HTML][HTML] Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategy
…, H Robinson, N Gossger, TM John, M Voysey… - Journal of infection, 2015 - Elsevier
Objectives Recent development of serogroup B meningococcal (MenB) vaccines highlights
the importance of pharyngeal carriage data, particularly in adolescents and young adults, to …
the importance of pharyngeal carriage data, particularly in adolescents and young adults, to …
Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose
MD Snape, P Saroey, TM John, H Robinson, S Kelly… - Cmaj, 2013 - Can Med Assoc
… Matthew Snape and Tessa John have received assistance to attend scientific meetings from
… Tessa John. The study organization, conduct and oversight was performed by Tessa John, …
… Tessa John. The study organization, conduct and oversight was performed by Tessa John, …
Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants
KP Perrett, MD Snape, KJ Ford, TM John… - The Pediatric …, 2009 - journals.lww.com
Background: The highest rate of invasive meningococcal disease is among children under
2 years of age. There is currently no licensed quadrivalent (serogroups A, C, W-135, and Y) …
2 years of age. There is currently no licensed quadrivalent (serogroups A, C, W-135, and Y) …
Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of …
MD Snape, J Philip, TM John, H Robinson… - The pediatric …, 2013 - journals.lww.com
Background: In a previous study, 60 infants receiving an investigational serogroup B
meningococcal vaccine containing recombinant meningococcal proteins alone (rMenB) or …
meningococcal vaccine containing recombinant meningococcal proteins alone (rMenB) or …
Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age
F McQuaid, MD Snape, TM John, S Kelly… - The Pediatric …, 2014 - journals.lww.com
Background: A serogroup B meningococcal vaccine (4CMenB) has been licensed by the
European commission for use in various infant schedules. However, data are limited on …
European commission for use in various infant schedules. However, data are limited on …
Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months
F McQuaid, MD Snape, TM John, S Kelly, H Robinson… - Cmaj, 2015 - Can Med Assoc
Background: The multicomponent serogroup B meningococcal (4CMenB) vaccine induces
antibodies against indicator strains of serogroup B meningococcus under various schedules. …
antibodies against indicator strains of serogroup B meningococcus under various schedules. …